APPswe as a risk factor for osteoporosis
APPswe as a risk factor for osteoporosis
批准号:
10224044
负责人:
WEN-CHENG XIONG
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2021-09-30
关键词:
AddressAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAlzheimer&aposs disease riskAmyloidAmyloid beta-Protein PrecursorAnimal Disease ModelsArchitectureAttenuatedBone DensityBone MarrowBone ResorptionBone TissueBone structureCell LineageCell surfaceCellsChronicClinical ResearchCognitiveDegenerative DisorderDementiaDeteriorationDevelopmentDiseaseDominant-Negative MutationEarly DiagnosisFamilyGenesGenetic studyGoalsHamstersHip FracturesHomeostasisImpairmentIntegral Membrane ProteinIronIron ChelationKnockout MiceLate Onset Alzheimer DiseaseLeadLigandsLinkMediatingMolecularMouse ProteinMusMutationNeurodegenerative DisordersOsteoblastsOsteoclastsOsteogenesisOsteoporosisOsteoporoticPathogenesisPathologicPhenotypePlayPopulationPresenile Alzheimer DementiaPreventive therapyPrionsProteinsProteolysisQuality of lifeResearchRisk FactorsRoleSignal TransductionSwedish mutationTestingTg2576Transgenic MiceVeteransWNT Signaling Pathwayage relatedagedbonebone masscell typegenomic locushepcidinin vivomacrophagemembermutantnovelosteoblast differentiationpromoterpublic health relevancereceptorrisk variantselective expressionskeletalsubstantia spongiosayoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
ABSTRACT Osteoporosis is a common skeletal degenerative disorder that is characterized by decrease of bone-mass and micro-architectural deterioration of bone tissue. It results from increased osteoclast (OC)-mediated bone resorption and/or reduced osteoblast (OB)-mediated bone formation. Alzheimer's disease (AD) is a common neurodegenerative disorder with cognitive dementia. Intriguingly, AD patients frequently have lower bone mineral density and higher rate of hip fracture, compared with the same age normal population. Several newly identified AD risk genes/loci encode proteins critical for osteoclastic activation and/or bone-mass homeostasis. Increasing evidence from clinical and genetic studies thus supports a degree of association of both disorders. However, very few studies are available to address the underlying mechanisms. The goal of this proposal is to determine if and how the Swedish mutant amyloid precursor protein (APPswe) acts as a risk factor for osteoporosis. APP is a ubiquitously expressed transmembrane protein. Its cleavage product, A, is believed to be a major culprit for both early- and late-onset AD. We thus explored the possible contribution of APPswe to AD- associated skeletal deficits in mice. Tg2576 mice express APPswe under the control of prion promoter, and develop AD-relevant neuro-pathologic deficits at older age (>10 months old). Remarkably, our preliminary studies revealed age-dependent osteoporotic deficits in this AD animal model, including reduced trabecular bone-mass in young adult age and deteriorated bone tissue at older age. The reduced bone-mass was associated with a decrease in osteoblastic bone formation and an increase in osteoclastic bone resorption. The deteriorated bone structure was preceded by an impaired osteoclastic bone resorption. To investigate underlying mechanisms, we generated a transgenic mouse that enables cell-type specific expression of APPswe in OBs and OCs. Our results suggest that APPswe plays a cell autonomous role in suppressing OB-mediated bone formation and in regulating OC activation. These results uncovered potentially novel cellular mechanisms by which APPswe disrupts bone homeostasis. However, underlying molecular mechanisms remain unclear. In this proposal, we will address this issue. This research will not only provide a potential link between AD and skeletal deficits, but also identify unrecognized functions of APP and APPswe, and reveal new pathophysiological mechanisms underlying osteoporosis and AD, both chronic degenerative disorders affecting many veteran's quality of life and highly relevant to Strategic Objectives of VA.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1083/jcb.201207154
发表时间:
2013-03-18
期刊:
The Journal of cell biology
影响因子:
--
作者:
[Xia WF, Tang FL, Xiong L, Xiong S, Jung JU, Lee DH, Li XS, Feng X, Mei L, Xiong WC]
通讯作者:
Xiong WC
DOI:
10.1002/jbmr.1954
发表时间:
2013-10
期刊:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
影响因子:
--
作者:
[Xia WF, Jung JU, Shun C, Xiong S, Xiong L, Shi XM, Mei L, Xiong WC]
通讯作者:
Xiong WC
DOI:
10.1038/s41419-018-1123-7
发表时间:
2018-10-22
期刊:
Cell death & disease
影响因子:
9
作者:
[Pan JX, Tang F, Xiong F, Xiong L, Zeng P, Wang B, Zhao K, Guo H, Shun C, Xia WF, Mei L, Xiong WC]
通讯作者:
Xiong WC
DOI:
10.1016/j.ebiom.2016.05.028
发表时间:
2016-07
期刊:
EBioMedicine
影响因子:
11.1
作者:
[Xiong L, Xia WF, Tang FL, Pan JX, Mei L, Xiong WC]
通讯作者:
Xiong WC
DOI:
10.1371/journal.pone.0139395
发表时间:
2015
期刊:
PloS one
影响因子:
3.7
作者:
[Guo JP, Pan JX, Xiong L, Xia WF, Cui S, Xiong WC]
通讯作者:
Xiong WC
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development
-
批准号:10254624
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:WEN-CHENG XIONG
-
依托单位:
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development
-
批准号:10513298
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:9605932
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2017
-
负责人:WEN-CHENG XIONG
-
依托单位:
APP as a common denominator for Alzheimer's disease and osteoporosis
-
批准号:9903240
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:WEN-CHENG XIONG
-
依托单位:
APP as a common denominator for Alzheimer's disease and osteoporosis
-
批准号:9607371
-
项目类别:
-
资助金额:$28.61万
-
财政年份:2016
-
负责人:WEN-CHENG XIONG
-
依托单位:
APP as a common denominator for Alzheimer's disease and osteoporosis
-
批准号:9323223
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2016
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:9059562
-
项目类别:
-
资助金额:$31.16万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:9486649
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:8708256
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:8842912
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Mechanisms of neuromuscular junction formation
-
批准号:10267688
-
项目类别:
-
资助金额:$56.87万
-
财政年份:2013
-
负责人:WEN-CHENG XIONG
-
依托单位:
Mechanisms of neuromuscular junction formation
-
批准号:10434135
-
项目类别:
-
资助金额:$56.41万
-
财政年份:2013
-
负责人:WEN-CHENG XIONG
-
依托单位:
Amyloid-RAGE Signaling in Bone Remodeling
-
批准号:8139580
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
APPswe as a risk factor for osteoporosis
-
批准号:9139032
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
Amyloid-RAGE Signaling in Bone Remodeling
-
批准号:8597386
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
Amyloid-RAGE Signaling in Bone Remodeling
-
批准号:8244935
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:7559625
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:8215796
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:7473548
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:7761689
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
海外基金